Pitäisikö Mannisen lanseerata oma Q10-valmiste?

Lisäsin oikeaan laitaan kyselyn:  

Pitäisikö Manninen Nutraceuticals Oy:n lanseerata oma Q10-valmiste? 

Jos kysyntää löytyy, lanseeraamme öljypohjaisen 40 mg:n Q10-valmisteen 200 kapselin purkissa.  Hinta on erittäin kilpailukykyinen ja kapselin sisältö on koostettu niin, että imeytyminen on mahdollisimman tehokasta. Tarkkaan ottaen formula sisältää ubikinolia eli pelkistynyttä ubikinonia. Öljypohjaisen ubikinolikapselin biologinen hyötyosuus on selvästi suurempi kuin ubikinonia sisältävän "kuivakapselin" (Evans ym. 2008).

Q10-supplementaation hyödyistä on kiisteltu jo vuosikausia, mutta ainakin osa väitetyistä terveysvaikutuksista pitää kutinsa.

Nutrition. 2010 Mar;26(3):250-4. Epub 2009 Nov 22.

Clinical aspects of coenzyme Q10: an update. 

Littarru GP, Tiano L. 

Source 

Department of Biochemistry, Biology and Genetics, Polytechnic University of the Marche, Ancona, Italy. g.littarru@univpm.it

Abstract

The fundamental role of coenzyme Q(10) (CoQ(10)) in mitochondrial bioenergetics and its well-acknowledged antioxidant properties constitute the basis for its clinical applications, although some of its effects may be related to a gene induction mechanism. Cardiovascular disease is still the main field of study and the latest findings confirm a role of CoQ(10) in improving endothelial function. The possible relation between CoQ(10) deficiency and statin side effects is highly debated, particularly the key issue of whether CoQ(10) supplementation counteracts statin myalgias. Furthermore, in cardiac patients, plasma CoQ(10) was found to be an independent predictor of mortality. Studies on CoQ(10) and physical exercise have confirmed its effect in improving subjective fatigue sensation and physical performance and in opposing exercise-related damage. In the field of mitochondrial myopathies, primary CoQ(10) deficiencies have been identified, involving different genes of the CoQ(10) biosynthetic pathway; some of these conditions were found to be highly responsive to CoQ(10) administration. The initial observations of CoQ(10) effects in Parkinson's and Huntington's diseases have been extended to Friedreich's ataxia, where CoQ(10) and other quinones have been tested. CoQ(10) is presently being used in a large phase III trial in Parkinson's disease. CoQ(10) has been found to improve sperm count and motility on asthenozoospermia. Moreover, for the first time CoQ(10) was found to decrease the incidence of preeclampsia in pregnancy. The ability of CoQ(10) to mitigate headache symptoms in adults was also verified in pediatric and adolescent populations.

 

Copyright (c) 2010 Elsevier Inc. All rights reserved.